JP Morgan analysts downgraded the shares of Moderna Inc. MRNA, + 15.93% Neutral because of overweight by concerns about the valuation of the preclinical company, which has never produced an approved product. Moderna is developing a candidate for the COVID-19 vaccine that is widely considered to be one of the …
Read More »JP Morgan downgrades Moderna’s rating due to valuation problems
